recombinant glucagon / Generic mfg. - LARVOL DELTA

Lupin Limited has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use Prefilled Pens and Glucagon for Injection vials. (Indian Pharma Post) - "Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus. Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza) had an estimated annual sale of USD 458 million in the U.S. (IQVIA MAT May 2025)...Glucagon for Injection USP, 1 mg/vial, packaged in an emergency kit, is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. It is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus...Glucagon for Injection USP, 1 mg/vial, had an estimated annual sale of US$ 124 million in the U.S. (IQVIA MAT May 2025)."

ANDA • Sales • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Glucagon: Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism (clinicaltrials.gov) - P=N/A; N=12; Recruiting; Sponsor: The University of Texas Health Science Center at San Antonio

New trial

Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy. (PubMed, Endocrinol Diabetes Metab Case Rep) - "All patients with a new diagnosis of glucagonoma should be assessed clinically for evidence of cardiac failure and, if present, a baseline transthoracic echocardiogram should be performed. In the presence of cardiac impairment these patients should be managed by an experienced cardiologist."

Journal